Scheie Eye Institute at the Perelman Center for Advanced Medicine, Philadelphia, PA, USA.
Center for Advanced Retinal and Ocular Therapeutics at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Transl Vis Sci Technol. 2023 Jan 3;12(1):28. doi: 10.1167/tvst.12.1.28.
To optimize a virtual reality (VR) orientation and mobility (O&M) test of functional vision in patients with inherited retinal degenerations (IRDs).
We developed an O&M test using commercially available VR hardware and custom-generated software. Normally sighted subjects (n = 20, ages = 14-67 years) and patients with IRDs (n = 29, ages = 15-63 years) participated. Individuals followed a dim red arrow path to a "course exit," while trying to identify nine obstacles adjacent to, or directly in their path. Dark-adapted subjects completed 35 randomly selected VR courses at increasing luminances, twice per luminance step, binocularly, and uni-ocularly. Performance was graded automatically by the software. Patients with IRD completed a modified Visual Function Questionnaire (VFQ).
Normally sighted subjects identified approximately 50% of the obstacles at the dimmest course luminance. Except for two patients with IRD with poor vision, all patients were able to complete the test, although they required brighter (by >2 log units) luminances to identify 50% of the obstacles. In a single-luminance screening test in which normal subjects detected at least eight of nine objects, most patients with IRD underperformed; their performance related to disease severity, as measured by visual acuity, kinetic visual field extent, and VFQ scores. Test-retest differences in object detection were similar to the differences between the two eyes (±2 SD = ±2 objects).
This VR-O&M test was able to distinguish subjects with IRDs from normal subjects reliably and reproducibly.
This easily implemented, flexible, and objectively scored VR-O&M test promises to become a useful tool to assess the impact that IRDs and their treatments have on functional vision.
优化遗传性视网膜变性(IRDs)患者虚拟现实(VR)定向和移动(O&M)功能视觉测试。
我们使用市售 VR 硬件和定制生成的软件开发了一种 O&M 测试。正常视力受试者(n = 20,年龄 = 14-67 岁)和 IRD 患者(n = 29,年龄 = 15-63 岁)参与了该测试。个体跟随昏暗的红色箭头路径到达“课程出口”,同时尝试识别九个位于其路径旁或直接位于其路径上的障碍物。暗适应受试者在增加的亮度下,双眼和单眼,每次亮度增加 2 次,随机完成 35 个 VR 课程。软件自动对性能进行分级。IRD 患者完成了改良的视觉功能问卷(VFQ)。
正常视力受试者在最暗的课程亮度下识别出大约 50%的障碍物。除了两名视力较差的 IRD 患者外,所有患者都能够完成测试,尽管他们需要更亮(增加>2 个对数单位)的亮度才能识别 50%的障碍物。在单亮度筛查测试中,正常受试者至少能识别出 9 个物体中的 8 个,大多数 IRD 患者表现不佳;他们的表现与疾病严重程度相关,如视力、运动视觉场范围和 VFQ 评分所示。物体检测的测试-再测试差异与双眼之间的差异相似(±2 SD = ±2 个物体)。
该 VR-O&M 测试能够可靠且可重复地区分 IRD 患者和正常受试者。
本文作者报道了一种新型的虚拟现实(VR)定向和移动(O&M)测试,用于评估遗传性视网膜变性(IRDs)患者的功能性视觉。该测试使用市售的 VR 硬件和定制软件,能够识别患者在模拟环境中的定向和移动能力,并与正常受试者进行比较。研究结果表明,该测试能够可靠地区分 IRD 患者和正常受试者,且具有良好的重复性。此外,该测试还能够反映患者的疾病严重程度和视觉功能。综上所述,该 VR-O&M 测试具有良好的应用前景,有望成为评估 IRDs 及其治疗方法对功能性视觉影响的有用工具。